Expert Interview
Discussing Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Ticker(s): ALNY- Neuromuscular subspecialist with interests in amyloid neuropathy, CIDP, myasthenia gravis and treats a large number of patients with these disorders.
- treats 75 patients with hATTR amyloidosis
- Very familiar with the data from the HELIOS-A and HELIOS-B trials of Vutrisiran
Roughly how many patients do you currently manage with hATTR amyloidosis?
Added By: sara_adminHow confident do you feel about the drugs efficacy and chance of approval given the data from the HELIOS-A and HELIOS-B trials of Vutrisiran?
Added By: sara_adminHow does Vutrisiran compare to the current standard of care and other treatment options for your patients?
Added By: sara_adminIf approved, do you expect to begin prescribing immediately?
Added By: sara_adminDo you think it being subcutaneously administered to patients, makes it preferable to other more invasive treatment options?
Added By: sara_adminDo you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
